Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 24 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
JUBILANT PHARMACEUTICALS from Merelbeke-Melle, company number BE0454891594, closed financial year 2025 with a result of € -239,918 after tax. For that financial year JUBILANT PHARMACEUTICALS recorded revenue of € 582,278 and equity of € -1 million. Compared with financial year 2024, the result moved from € -180,559 to € -239,918. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on October 6, 2025.
€ -1 million
▼ € 239,918 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -239,918
▼ 33 % more loss than in 2024
Profit after tax over the fiscal year.
€ 27,370
▲ 27% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -2.1 million.
People and assets in 2025
€ 902
▲ 28% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 156,808
▼ 28% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 69 days on average.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 612,805 | € 679,802 | € 953,015 | € 582,278 | ▼ 39% |
| Profit after taxes | € -72,794 | € -128,063 | € -180,559 | € -239,918 | ▼ € 59,360 |
| Equity | € -497,926 | € -625,989 | € -806,548 | € -1,046,466 | ▼ € 239,918 |
| Total debts | € 1,228,595 | € 1,289,821 | € 1,294,650 | € 1,382,322 | ▲ 7% |
| Cash | € 13,429 | € 136,163 | € 21,509 | € 27,370 | ▲ 27% |
| Retained profit | € -1,548,226 | € -1,676,289 | € -1,856,848 | € -2,096,766 | ▼ € 239,918 |
| Balance sheet total | € 730,669 | € 663,832 | € 488,102 | € 335,856 | ▼ 31% |
Key figures of JUBILANT PHARMACEUTICALS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 October 2026.
What happened to JUBILANT PHARMACEUTICALS?
What happened at JUBILANT PHARMACEUTICALS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 239,918. Source: NBB ↗
- New establishment in Merelbeke-Melle. KBO
- Start of the company according to the CBE. KBO
In short
From € 72,794 loss in 2022 to € 239,918 loss in 2025.
Pays suppliers within 69 days on average.
A new publication or filing at JUBILANT PHARMACEUTICALS? We notify you, reason included.
Follow JUBILANT PHARMACEUTICALSDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of JUBILANT PHARMA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
JUBILANT PHARMACEUTICALSBehind JUBILANT PHARMACEUTICALS are Guilliano Perfetti, Rajesh Bhatia, Rajpal Dr. Jaidev Sanjeev and Michael Van Ohlen. The shares are held by JUBILANT PHARMA (99.8%).
Directors
According to the 2025 annual accounts
Rajesh Bhatia
Director
Rajpal Dr. Jaidev Sanjeev
Director
Shareholders
99.8%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Guldensporenpark 22
9820 Merelbeke-Melle
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0454.891.594
- VAT number
- BE 0454.891.594
- Registered office
- Guldensporenpark 22, 9820 Merelbeke-Melle
- Names & denominations
- JUBILANT PHARMACEUTICALS · JUBILANT
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 14 April 1995
- Peppol
- Active · Active since 22 Dec 2025
- Activities · NACE
Overige rechtskundige dienstverlening